NCT05251493
Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: The monograph for the investigational drug (derisomaltose) was updated to include pregnancy as an indication for infusion. Enrollment significantly decreased and the study was stopped. Show 8 more changesShow less
- Eligibility criteria expanded, about 27 words
- Final enrollment: 113 participants (planned 280)
- Primary completion date changed from estimate of Dec 31, 2026 to May 31, 2026
- Study completion date changed from estimate of Feb 28, 2027 to Jun 1, 2026
- Secondary endpoints: details revised at 5 of 5 entries
- Study description revised
- Site details revised
- Publications: details revised at 8 of 8 entries
- Notable Primary completion date: Dec 31, 2024 to Dec 31, 2026
- Study completion date: Feb 28, 2025 to Feb 28, 2027
- Notable Primary completion date: May 31, 2023 to Dec 31, 2024
- Study completion date: May 31, 2023 to Feb 28, 2025
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Study sites: 0 to 1
- Primary and study completion dates: May 2023 to May 31, 2023
- Start date changed from estimate of May 2022 to Jun 6, 2022
- Secondary endpoints revised (5)
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Correction of anemia
Timeframe: 30 days post iron infusion
Secondary (5)
Participant's tolerance to IV iron infusion
Comparison of participant's pregnancy related symptoms- subjective measure
Convenience/barriers of IV iron appointment(s)- subjective measure
Changes in Participant's Mental Health and Physical Well-Being
Reported bonding with baby-subjective
Arms and interventions
Iron Isomaltoside/ferric derisomaltoseActive comparator
route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)
Iron SucroseActive comparator
Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table
Drugs: Iron Isomaltoside 1000, ferric derisomaltose, Iron sucrose
Sites
1 site in 1 country
- Regina General HospitalRegina, Saskatchewan, Canada